Related Experiment Video
Updated: May 25, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
Propranolol's potential to increase survival time in a disabled submarine
Seth A Reini1, David M Fothergill, Heath G Gasier
1Naval Submarine Medical Research Laboratory, Groton, CT, USA. seth.reini@med.navy.mil
Background:
While awaiting rescue from a disabled submarine, survivors will likely endure an atmosphere of rising CO2 that will result in CO2 toxicity once the available emergency CO2 scrubbing materials are exhausted. Propranolol is a beta-blocker that may increase survival time by reducing metabolic CO2 production (VCO2). The purpose of this study was to determine if propranolol reduces resting VCO2 in healthy men.
Methods:
Eight healthy men completed a counterbalanced, randomized, placebo-controlled, double-blinded crossover study in which each subject received propranolol (40 mg twice daily) or placebo (lactose pill twice daily) over 72 h. The alternate condition was separated by a minimum 96-h washout period. Resting VCO2, oxygen consumption (VO2), ventilation (VE), respiration rate (RR), respiratory exchange ratio (RER), mean arterial pressure (MAP), heart rate (HR), and cardiac output (Q) were measured each morning and afternoon.
Results:
When compared to placebo, propranolol significantly reduced VCO2 (-6.5%), MAP (-3.6%), HR (-10.4%), and Q (-8.2%); however, there were no significant differences in VO2, RR, VE, or RER.
Discussion:
These results show that 40 mg of propranolol taken twice daily reduces resting VCO2 in healthy men and suggests that this treatment strategy may increase survival time in a disabled submarine scenario.
Related Concept Videos
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Heart Failure Drugs: β-Blockers
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Heart Failure Drugs: Inotropic Agents
